Comparative Pharmacology
Head-to-head clinical analysis: PIQRAY versus VIJOICE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIQRAY versus VIJOICE.
PIQRAY vs VIJOICE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PIQRAY (alpelisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3Kα. It inhibits the PI3K/AKT/mTOR signaling pathway, reducing cell proliferation and survival in PIK3CA-mutated cancer cells.
Phosphoinositide 3-kinase (PI3K) inhibitor that selectively inhibits PI3Kδ (delta isoform) with less activity against PI3Kγ. It blocks the PI3K/AKT/mTOR signaling pathway, reducing proliferation and survival of malignant B cells.
300 mg orally twice daily with food, taken as two 150 mg tablets.
Adult: 200 mg orally twice daily, with or without food.
None Documented
None Documented
The terminal elimination half-life is 12 hours (range 9-17 hours), supporting twice-daily dosing.
Terminal elimination half-life is approximately 50–100 hours. Due to this long half-life, steady-state is reached after about 2–3 weeks of daily dosing, allowing for once-daily administration.
Following a single oral dose of [14C]-PIQRAY, 81% of the radioactivity was recovered in feces (70% unchanged) and 14% in urine (7% unchanged).
Primarily biliary excretion (≈89% of dose recovered in feces as parent drug and metabolites). Renal excretion accounts for <2% of the dose as unchanged drug.
Category C
Category C
PI3K Inhibitor
PI3K Inhibitor